SynthesisJournal of translational medicine2026
Efficacy and safety of AAV RPGR gene therapy in X-linked retinitis pigmentosa: a systematic review and meta-analysis.
Synthesis in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundX-linked retinitis pigmentosa (XLRP) represents a severe inherited retinal dystrophy associated with pathogenic variants in the retinitis pigmentosa GTPase regulator (RPGR) gene. Adeno-associated virus (AAV)-mediated RPGR gene augmentation is designed to preserve photoreceptor structure and function.
objectivesThe purpose of this study was to critically appraise and quantitatively synthesize the efficacy and safety evidence for AAV-RPGR gene therapy in X-linked retinitis pigmentosa.
methodsScopus, PubMed, the Cochrane Library, ScienceDirect, and Google Scholar were searched from inception through July 11, 2026. Two reviewers independently screened records, two reviewers assessed risk of bias, and extracted data were verified by a second reviewer. Proportions were synthesized using inverse-variance fixed-effect logit models with a 0.5 continuity correction for zero or all-event cells; DerSimonian-Laird random-effects models were used as sensitivity analyses. Cohort linkage, dose-stratified safety, and overlap-adjusted analyses were performed.
resultsThe search identified 571 records and included 12 clinical reports. Pooled retinal sensitivity improvement was 73.8% (95% confidence interval, 56.0%-86.1%; 25/33 participants), and pooled visual function improvement was 52.3% (95% confidence interval, 38.0%-66.2%; 28/52 participants). The pooled adverse-event proportion was 42.6% (95% confidence interval, 27.2%-59.5%; 42/90 participants), intraocular inflammation was 45.5% (95% confidence interval, 34.6%-56.8%; 36/81 participants), and intraocular-pressure elevation was 34.9% (95% confidence interval, 24.2%-47.4%; 22/63 participants). Product-specific dose analyses showed greater inflammatory or ocular serious adverse-event frequencies at higher vector exposure.
conclusionAAV-RPGR gene therapy demonstrates clinically relevant functional signals across multiple outcome domains with a structured and monitorable ocular safety profile. Cohort-linked synthesis, dose-specific interpretation, standardized outcome definitions, and long-term multinational follow-up provide a rigorous framework for subsequent clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.